Autism Speaks to make Google-underpinned genomics database freely available

Autism Speaks has released details of the genome sequencing database it is building on Google's cloud platform. The plan is to sequence the whole genomes of 10,000 people in families affected by autism and make the resulting database freely available to researchers.

Transcriptic offers Y Combinator biotechs $20,000 credit for its robotic labs

The 10 biotechs in the latest batch of Y Combinator startups--as well as those that have already graduated from the incubator--will receive $20,000 to spend at Transcriptic's automated life science laboratory.

Flatiron maintains dealmaking pace with patient-reported outcome data hookup

One week after striking a deal with Foundation Medicine, Google Ventures-backed cancer analytics firm Flatiron Health has hooked up with Vector Oncology to advance its clinical research and real-world evidence activities.

Paul Allen donates $100M to create cell science institute

Microsoft co-founder Paul Allen has once again dipped into his personal fortune to advance science. The latest venture sees Allen donate $100 million to create a cell science center with a heavy reliance on IT.

Documents reveal FDA's use of computer forensics to uncover data falsification

In 2011, a Sun Pharma technician gave into temptation, hit the delete key and generated new, positive data from another sample within the same batch. In 2013, the FDA uncovered what had happened and tasked its computer forensics experts with finding other such events. The team discovered 5,301 more deleted chromatography results from the same facility.

Ex-Pfizer SVP named CEO of BioClinica

BioClinica has named John Hubbard as its new CEO. Hubbard joins the company from Pfizer, where he worked as senior vice president and worldwide head of development operations.

Flatiron Health teams with Foundation Medicine to develop oncology platform

Flatiron Health has revealed part of how it plans to develop into the disruptive force in cancer drug R&D that investors envisaged when they gave it $130 million in May. The latest piece of the plan is a deal with testing firm Foundation Medicine, which will contribute genomic profiling data to a cancer analytics platform.

Hackers use Wall Street know-how to steal stock-moving biotech info

Biotech IT security teams were just presented with another headache. A team of Western, Wall Street insiders is believed to be breaking into biopharma company emails in pursuit of information on drug development results, takeovers and other events likely to affect share prices.

23andMe gets regulatory thumbs-up to sell DNA tests in U.K.

23andMe has found regulators in the United Kingdom more amenable to its personal genomics service than the U.S. FDA. The U.K. Medicines and Healthcare Products Regulatory Agency has given cautious backing to the company's spit test, which has a CE mark clearing it for sale in Europe.

Google's Calico begins search for a head of bioinformatics

A choice bioinformatics position just opened up at Calico. The secretive, Google-backed anti-aging biotech is recruiting a head of bioinformatics to lead the creation of infrastructure and tools for acquiring and processing sequence data.

Humana agrees to contribute information to PearlDiver's database

Humana has opened up another way for healthcare researchers to access its vault of data. The insurance giant has agreed to add its information to PearlDiver's database, a resource that at the last count contained 1.1 billion HIPAA-compliant patient records.

Monocl Software bags grant for KOL assessment platform

Monocl Software has taken a step toward its goal of introducing an analytic platform for finding and assessing life science experts in 2015. The Swedish innovation agency Vinnova has helped Monocl toward its target by awarding it funding under its digital health program.

U.K. heavyweights commit $16M to Oxford Uni genome data analysis spinout

Heavyweights of the United Kingdom biotech investing scene have backed Genomics, a spinout from the University of Oxford that is developing a genome data analysis platform. Genomics is working with unnamed pharmaceutical companies to apply the platform to drug development.

Medidata tips wearables data to enter regulatory filings by 2020

Medidata president Glen de Vries has predicted drug developers will begin presenting digital biomarkers as evidence to regulators and payers within five years, Outsourcing-Pharma reports.

Nvidia backs projects to tap GPUs for cancer research

The Nvidia Foundation has awarded $400,000 to computational cancer projects at the Dana-Farber Cancer Institute and Stanford University. Nvidia backed the two projects--which took an equal split of the funding--as part of an initiative to finance programs that use parallel computing to advance cancer research.

Texas' $3B cancer agency makes computational biology a priority

The Cancer Prevention and Research Institute of Texas has responded to scandals that put it out of action for a year with a report detailing how it plans to use its $3 billion war chest. In the report, CPRIT lists computational biology as one of 7 proposed priorities for its $300-million-a-year funding program.

NCI sees role for feds in validating, processing wearables data

A program director at the National Cancer Institute has outlined his vision for how federal IT initiatives can help healthcare adapt to the rise of wearables and ever larger datasets. The process will begin by identifying the core analytic and IT system components all researchers need, regardless of whether they are focused on cancer, diabetes or other diseases.

Johns Hopkins, Scripps create modeling tools for Ebola R&D

Top academic centers have contributed structural modeling tools to the push to develop treatments for Ebola. A team at Scripps is behind the first tool, which is designed to show researchers which parts of the Ebola virus to target.

NIH cites European precedent in call for disclosure of clinical trial data

If the U.S. National Institutes of Health gets its way, any researcher it funds will have to publish a summary of their clinical trial results and adverse events, regardless of whether the trial succeeded or failed.

Cambrian raises $10M for DNA printing tech used by GSK

Proponents of DNA printing have heralded it as a way to do everything from bringing alien life back from Mars to delivering vaccines in the event of a pandemic. And the technology has attracted GlaxoSmithKline and Roche, both of which have taken an interest in Cambrian Genomics.